Get Your Development Program Started on the Right Foot
-
Upload
brook-white-pmp -
Category
Health & Medicine
-
view
868 -
download
2
Transcript of Get Your Development Program Started on the Right Foot
A Full-Service CRO
Get Your Development Program Started on the Right Foot…
Presenter Introduction
Senior Vice President, R&D
David Shoemaker, PhD
Senior Medical Officer
Jack Modell, MD
Senior Research Scientist
Dana Minnick, PhD
Senior Research Scientist
Scott Burian, PhD
Overview
• Overview• Content• Example
Target Product Profile
• Overview• Clinical Development Plans• Nonclinical Development Plans• CMC• Regulatory Strategy
Integrated Product Development Plans
What is a TPP?• Key strategic planning document that:
– Provides a clear understanding of requirements and expectations of the ultimate outcome of product development
– Is driven by unmet patient, physician and payer needs at time of launch
• Roadmap of key Go/No-Go decision points • Statement of the overall intent of the product
development program– and much more than just a draft product label
What is a TPP?
A differentiated value proposition Snapshot in time
Summary of studies that justify labeling claims
Dynamic & multidisciplinary document
Communication tool Starting point for annotated package insert (label)
Link to FDA Guidance
The purpose of a TPP is to provide a format for discussions that can be used throughout the drug development process. The TPP embodies the notion of beginning with the goal in mind.
The TPP provides a statement of the overall intent of the drug development program, and gives information about the drug at a particular time in development.
The TPP is a dynamic summary that changes as knowledge of the drug increases.
Road Map for Development
• Focuses development • Required studies – no more, no less –
become apparent• Requires comparison with similar
products• Constant updating of indication
required– With new information from your studies
& market– Go/No-Go decision points are forced
When is the TPP Needed?
• As early in development as possible– Pre-IND Meeting – IND– End-of-Phase 1 Meeting– End-of-Phase 2 Meeting – Annotated Package Insert Template– Pre-NDA or -BLA Meeting
Establish the Targets Early
• Begin with the end in mind– “If you don’t know where you’re going,
you’ll be lost when you get there.” Yogi Berra• Interdisciplinary activity
– Project teams (Clinical/Nonclinical/CMC/Regulatory)
– Labeling and marketing teams• Initial interdisciplinary and senior
management input and buy-in• Decision log
– Conflict resolution system– Go/No-Go rationale
Typical TPP Checklist Includes:• Scientific rationale• Preclinical support• Toxicology/ADME/PK• Acute vs. chronic indication• Unmet need• Clear diagnostic criteria• Target population or
subpopulation• Clinical plan• Anticipated safety profile, drug
interactions• Contraindications
• Regulatory plan• Endpoints (with estimate of
needed benefit)• Manufacturing/stability issues• Route of administration• Anticipated storage conditions• Desired shelf life• FDA guidelines available• International objectives• Competition• Patents
Indications and UsageTarget• What is the drug product? • Is it for treatment or prevention? • What disease/condition and unmet needs does it target? • Who are the target patients?
Annotations in TPP• Completed/planned studies supporting the target
Comments• Summarize the drugs currently used for treatment or
prevention in your target indication and write a brief statement on their competitive positioning
Dosage and Administration
Target
• How much drug is required?
• How is it administered?
• How often is the treatment?
• What is the duration of treatment?
Annotation
• Summarize completed & planned studies that support the safety and effectiveness of the proposed dosage and route of administration
Comments
• Summarize the positioning of the dosage and administration relative to current treatments
Adverse ReactionsTarget
• What adverse effects might be anticipated based on results of nonclinical studies?
• What adverse effects might be expected due to the drug class?
• What adverse effects have been observed in clinical studies?
• What adverse effects are acceptable based on product risk-benefit and positioning?
Annotation• Summarize
completed/planned studies that support the target (include references to reported class-related drug effects)
Adverse Reactions
Comments
• Identify AEs associated with current drug treatments that might be mitigated by your new drug candidate
Considerations
• Similar product monographs
• Acceptable thresholds for incidence of AEs
• Opportunities to demonstrate superior safety profile
Clinical StudiesTarget:
Statements regarding efficacy &
safety benefits• Clinical evidence to
support the indication claims
• Strength of evidence
• The safety profile• Endpoints in the
clinical studies to support the competitive positioning and marketing strategy for the new drug
Annotation
• Summarize completed/planned studies that will develop evidence in support of treatment
Comments
• Identify key areas of competitive advantage
Additional Considerations
Nonclinical requirements Enrollment challenges Time to market
Groundwork for subsequent indications Biomarkers Companion diagnostics
Common Pitfalls• Interdisciplinary input not sought• Late stakeholder buy-in• “Interest group”-driven targets • Lack regulatory intelligence• No prospective key decision points• Failure to revisit when new data obtained• Failure to use it as a tool for planning, development,
communication
Example Starting Point: Novel antidepressant
• Currently marketed AD’s are only effective in about 50% of patients because of problems with tolerability and/or lack of efficacy
• Currently marketed AD’s have relatively few significant drug interactions
• Currently marked AD’s are generally given once-daily
• Currently marketed AD’s, when they do work, may require a few weeks for significant effect
• The world doesn’t need another expensive variation of a currently marketed antidepressant
What’s known
Example: Novel antidepressant
• A once-daily antidepressant, with no significant drug interactions, and one or more of the following:• Rapid onset (placebo separation by the
end of the first week)• Good tolerability, including no sexual
dysfunction, weight gain, or sedation• Robust efficacy greater than that of
currently marketed AD’s (and not less than)
What’s needed
General Development Flowchart
Diagram source: http://qb3.org/sites/qb3.org/files/QB3Podcast20120316_2_0.pdf
Integrated Product Development Plan
(IPDP)A strategic plan covering all
components of the drug development spectrum for a
product
IPDP Transformation to Label
Integrated Product
Development Plan
Target Product Profile
Product Label (prescriber’s Information)
Collect data, revisit, refine
IPDP
Label Claim
Nonclinical
ClinicalCMC
Strategic & dynamic toolUnique & integratedGoals, activities, contingencies‘Go/no go’ decision pointsCompetitive landscapeTarget Markets
Begin with the End in Mind
•Label claims•Efficacy•Safety
Market Approval
• Intended indication & population•Efficacy•Safety
Phase III
•Target indication & population•Proof of concept•First in humans
Phase I-II•Preclinical & quality (CMC) data to support human exposure•GLP safety and toxicology testing
•Stability of IP
File IND/CTA
“The End”
Now expand on this to include all activities required to enable each other to occur…
Comprehensive & Evolving
End Goal
Plan
Evaluate
Go/No Go
Decision
Revise
From TPP!!!
New Data
A Full-Service CRO
Production
Chemistry
Pharmaceutics
Pharmacology andPharmacokinetics
Toxicology
Regulatory
Clinical
DrugSelection
18+ Mo.18 Mo. 6 Mo. 18 Mo.12 Mo. 12 Mo.24 Mo.
Phase I Phase II Phase III Data Analysis
ISS/ISE/ERs
Phase IV
Safety inhealthy
volunteers
Efficacy& safetysmallgrouppatients
Pivotallargegrouppatients
NDA PrepareSubmit
FDA Review
NDAApproval
Post-marketSurveillance
INDPrepareSubmit
PilotPlant
GMP Plant Stability, Validation Production
Formulation, Dose & Administration Stability, Tech Transfer, Validation
Healthyhumans
Humanpatients
ADME (animal)
Mutagenicity
Acute ToxicitySub-acute Toxicity
Long-term Feeding Studies (chronic toxicity and carcinogenicity)
Reproductive Toxicology
8 Years
PRODUCT DEVELOPMENT
PopPK
DISCOVERY
1O Pharm 2O Pharm
1 Year +
IPDP Basic Content
Regulatory history and strategy
Chemistry, manufacturing, & controls (CMC) plan
Nonclinical (pre-clinical) development plan
Clinical development plan
Elements of the target label (target product profile)
Introduction
Mapping TPP to IPDP for Novel AntidepressantTPP• Global market• Once daily oral dosing, rapid
onset, chronic• Multiple dose strengths • Adults and elderly with
major depression• Efficacy superior to placebo,
similar/better versus gold standard
IPDP• Phase 3 studies (US, non-
US)• Phase 2 studies• Clinical pharmacology• Nonclinical studies• Chemistry, Manufacturing
and Controls• Regulatory • Marketing
Mapping TPP to IPDP for Novel AntidepressantTPP• Global market• Once daily oral dosing, rapid
onset, chronic• Multiple dose strengths • Adults and elderly with
major depression• Efficacy superior to placebo,
similar/better versus gold standard
IPDP• Phase 3 studies (US, non-
US)• Phase 2 studies• Clinical pharmacology• Nonclinical studies• Chemistry, Manufacturing
and Controls• Regulatory • Marketing
Mapping TPP to IPDP for Novel AntidepressantTPP• Global market• Once daily oral dosing, rapid
onset, chronic• Multiple dose strengths • Adults and elderly with
major depression• Efficacy superior to placebo,
similar/better versus gold standard
IPDP• Phase 3 studies (US, non-
US)• Phase 2 studies• Clinical pharmacology• Nonclinical studies• Chemistry, Manufacturing
and Controls• Regulatory • Marketing
Mapping TPP to IPDP for Novel AntidepressantTPP• Global market• Once daily oral dosing, rapid
onset, chronic• Multiple dose strengths • Adults and elderly with
major depression• Efficacy superior to placebo,
similar/better versus gold standard
IPDP• Phase 3 studies (US, non-
US)• Phase 2 studies• Clinical pharmacology• Nonclinical studies• Chemistry, Manufacturing
and Controls• Regulatory • Marketing
TPP IPDP• Favorable side effect profile
versus gold standard (sedation, weight gain, sexual dysfunction)
• Minimal/no drug interactions
• No cardiovascular safety issues
• Phase 3 studies (US, non-US)
• Phase 2 studies• Clinical pharmacology• Nonclinical studies• Chemistry, Manufacturing
and Controls• Regulatory • Marketing
Mapping TPP to IPDP for Novel Antidepressant
TPP IPDP• Favorable side effect profile
versus gold standard (sedation, weight gain, sexual dysfunction)
• Minimal/no drug interactions
• No cardiovascular safety issues
• Phase 3 studies (US, non-US)
• Phase 2 studies• Clinical pharmacology• Nonclinical studies• Chemistry, Manufacturing
and Controls• Regulatory • Marketing
Mapping TPP to IPDP for Novel Antidepressant
Clinical Development Plan• Phase 3
– Focus on efficacy and safety– Pivotal or confirmatory if adequate, well-controlled and agreed
with FDA– Target population & regimen for market– Generally at least 2 studies required– Major basis for marketing approval decisions and label
• Phase 2– Focus on efficacy and safety, proof-of-concept– Population - patients with target disease– Dose range finding, dose selection for phase 3– Further define outcomes/endpoints, population
• Phase 1– Focus on safety, pharmacokinetics, pharmacodynamics– First in human, SAD, MAD– Drug interactions, Thorough QT, food effect, bioavailability
Nonclinical Development Plan• Comprehensive assessment of the pharmacology,
pharmacokinetics, and toxicity of the drug substance and product
• How are data used?– Dose selection for initial clinical trials– Pharmacodynamics, MOA, biomarker development– Therapeutic index– Specific safety monitoring, use in specific populations– Labeling
• GLP requirement for some studies• Dose selection is critical for safety studies
Chemistry, Manufacturing, & Controls (CMC) Plan• Assure proper identification, quality, purity and
strength• Manufacture active pharmaceutical ingredient
(API)• Analytical assay development & validation• Pre-formulation/formulation development• Manufacture of Clinical trial material
– Release testing– Packaging and labeling– Comparators (active or placebo)
• Stability
Regulatory Strategy• Filing Pathway
– 505(b)(1), 505(b)(2), 505(j), drug-device combination
– What data are required for each pathway– Pertinent regulatory hurdles
• Understand competition– Review labels, SBAs, EPARs, financial reports
• Awareness of region specific regulations– ICH– FDA– EMA
Regulatory Strategy
• Orphan Drug Designation• Qualify for acceleration mechanisms?
– Breakthrough Therapy– Accelerated Approval – Priority Review
Know your drug to take advantage of these programs!
Type B Development Meetings with FDA
• Pre-IND Meeting
• End of Phase 1 Meeting
• End of Phase 2 Meeting
• Pre-NDA Meeting
Initial Agency Interactions• Pre-IND
– Obtain Agency buy-in on: • Clinical protocol• Nonclinical safety studies• CMC program
• What is required:– IPDP in Briefing Document– Well-written questions
• No open-ended questionsWhen is the right time to schedule meeting???
Avoiding Delays (e.g., Clinical Hold)• Unfocused development plans are
doomed to lead to delays• CDER receives approx. 1500 IND
submissions per year• Lapteva and Pariser (Journal of Investigative Medicine,
2016)
– In 2013, 9.0% were placed on clinical hold
– Most commonly cited reasons• CMC• Clinical • Toxicology
Common Reasons for Clinical Hold• Poorly organized submission and/or insufficient information• Inadequate information to assess safety• Clinical study design too aggressive, lacks needed safety
monitoring, dose limiting toxicity is not well defined and/or stopping rules inadequate, inadequate inclusion/exclusion criteria
• Unqualified impurities, excipients in clinical batch or poorly defined impurity profile
• Drug product not stable throughout the testing program• NOAEL not determined in toxicity study(ies)